IS8540A - Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma - Google Patents

Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma

Info

Publication number
IS8540A
IS8540A IS8540A IS8540A IS8540A IS 8540 A IS8540 A IS 8540A IS 8540 A IS8540 A IS 8540A IS 8540 A IS8540 A IS 8540A IS 8540 A IS8540 A IS 8540A
Authority
IS
Iceland
Prior art keywords
tweak
modulate
inhibit
adjustments
inhibitors
Prior art date
Application number
IS8540A
Other languages
English (en)
Inventor
Schneider Armin
Rossner Moritz
Vogt Gerhart
Schwaninger Markus
Original Assignee
Axaron Bioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axaron Bioscience Ag filed Critical Axaron Bioscience Ag
Publication of IS8540A publication Critical patent/IS8540A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
IS8540A 2004-02-23 2006-09-15 Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma IS8540A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04004094A EP1566636A1 (en) 2004-02-23 2004-02-23 Use of Tweak modulators and inhibitors for the treatment of neurological conditions
PCT/EP2005/001921 WO2005080972A1 (en) 2004-02-23 2005-02-23 Use of tweak modulators and inhibitors for the treatment of neurological conditions

Publications (1)

Publication Number Publication Date
IS8540A true IS8540A (is) 2006-09-15

Family

ID=34707372

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8540A IS8540A (is) 2004-02-23 2006-09-15 Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma

Country Status (16)

Country Link
EP (2) EP1566636A1 (is)
JP (1) JP2007532482A (is)
KR (1) KR20070029677A (is)
CN (1) CN1985169A (is)
AT (1) ATE504600T1 (is)
AU (1) AU2005214843A1 (is)
BR (1) BRPI0507959A (is)
CA (1) CA2558770A1 (is)
DE (1) DE602005027322D1 (is)
EA (1) EA200601547A1 (is)
IL (1) IL177285A0 (is)
IS (1) IS8540A (is)
MX (1) MXPA06009518A (is)
NO (1) NO20064293L (is)
WO (1) WO2005080972A1 (is)
ZA (1) ZA200606840B (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007163A (es) 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
MX352180B (es) 2002-04-09 2017-11-13 Biogen Ma Inc El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
WO2006089095A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
AU2011239311B2 (en) * 2005-02-17 2014-05-22 Biogen Ma Inc. Treating Neurological Disorders
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
MEP35408A (en) 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
EP1876448A1 (en) * 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
EP2545938A1 (en) 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies
US9068004B2 (en) 2010-02-04 2015-06-30 University Of Louisville Research Foundation, Inc. TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
AU2012225246B2 (en) 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276110A (en) 1978-11-30 1981-06-30 Yardney Electric Corporation Method of forming a separator integral with an electrode
US6379882B1 (en) * 1998-09-14 2002-04-30 Elan Pharmaceuticals, Inc. Method for selecting compounds for treating ischemia-related cellular damage
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
AU8901901A (en) * 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background

Also Published As

Publication number Publication date
AU2005214843A1 (en) 2005-09-01
KR20070029677A (ko) 2007-03-14
WO2005080972A1 (en) 2005-09-01
MXPA06009518A (es) 2007-03-23
EA200601547A1 (ru) 2006-12-29
NO20064293L (no) 2006-09-22
DE602005027322D1 (de) 2011-05-19
ATE504600T1 (de) 2011-04-15
JP2007532482A (ja) 2007-11-15
EP1721157B1 (en) 2011-04-06
CN1985169A (zh) 2007-06-20
BRPI0507959A (pt) 2007-07-17
IL177285A0 (en) 2006-12-10
EP1566636A1 (en) 2005-08-24
ZA200606840B (en) 2008-05-28
CA2558770A1 (en) 2005-09-01
EP1721157A1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
TWI372061B (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
EP1481077A4 (en) MITOTIC KINESINE HEMMER
WO2007022506A3 (en) Methods and compositions for treating neurological disease
GEP20084420B (en) Use of imidazole compounds for the treatment of neurodegenerative disorders
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
IS8540A (is) Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
WO2004058700A3 (en) Mitotic kinesin inhibitors
EP1551812A4 (en) MITOTIC KINESINE HEMMER
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
MY146548A (en) Certain chemicals entities, compositions, and methods
ATE446094T1 (de) Mitotische kinesin-hemmer
WO2004058148A3 (en) Mitotic kinesin inhibitors
EP1463733A4 (en) INHIBITORS OF MITOTIC KINESINE
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
NO20080969L (no) 1,2-diarylimidazoler for anvendelse som CBI-modulatorer
UA81423C2 (en) PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
EA200970817A1 (ru) Лекарственная форма, содержащая 1{6-[(3-циклобутил-2,3,4,5-тетрагидро-1н-3-бензазепин-7-ил)окси]-3-пиридинил}-2-пирролидинон или его соль и стабилизатор, который уменьшает его деградацию
DE602005025941D1 (de) Alpha-Aminoamid-Derivate zur Behandlung von Suchtstörungen
ATE494008T1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden